Sixteen years of cardiac transplantation

the Columbia Presbyterian Medical Center experience 1977 to 1993.

Robert E. Michler, J. M. Chen, D. M. Mancini, K. Reemtsma, E. A. Rose

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Cardiac transplantation is currently recognized as the best therapy available for the treatment of endstage heart disease. Since 1977, more than 650 cardiac transplants have been performed at CPMC, with a one-year survival rate currently approaching 85% and a 5-year survival rate approaching 65%. Throughout the 16-year experience with cardiac transplantation at CPMC, the criteria of eligibility for both donor and recipient candidates have been expanded to include older patients. In addition, pediatric patients requiring complex arterial or venous reconstruction and patients with elevated, but reversible pulmonary vascular resistance have been transplanted with excellent results. With the evolution of prolonged posttransplant survival has come a new group of complications associated with chronic long-term immunosuppressive therapy. These, and issues relating to cardiac retransplantation, continue to increase, largely because of the critical lack of organ donors. Continued efforts are being developed to optimize and reduce the total amount of immunosuppression administered postoperatively. Currently, research interests at CPMC include therapy for transplant coronary artery disease, left ventricular assist devices, and xenotransplantation. Ongoing investigations in these and other areas of transplantation have been established to encourage continued growth both within the field and at CPMC through the 21st century.

Original languageEnglish (US)
Pages (from-to)109-118
Number of pages10
JournalClinical transplants
StatePublished - 1993
Externally publishedYes

Fingerprint

Heart Transplantation
Survival Rate
Tissue Donors
Transplants
Heterologous Transplantation
Heart-Assist Devices
Therapeutics
Immunosuppressive Agents
Vascular Resistance
Immunosuppression
Coronary Artery Disease
Heart Diseases
Transplantation
Pediatrics
Survival
Growth
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sixteen years of cardiac transplantation : the Columbia Presbyterian Medical Center experience 1977 to 1993. / Michler, Robert E.; Chen, J. M.; Mancini, D. M.; Reemtsma, K.; Rose, E. A.

In: Clinical transplants, 1993, p. 109-118.

Research output: Contribution to journalArticle

@article{2e814810e2bf4403a1476e82e1e8e484,
title = "Sixteen years of cardiac transplantation: the Columbia Presbyterian Medical Center experience 1977 to 1993.",
abstract = "Cardiac transplantation is currently recognized as the best therapy available for the treatment of endstage heart disease. Since 1977, more than 650 cardiac transplants have been performed at CPMC, with a one-year survival rate currently approaching 85{\%} and a 5-year survival rate approaching 65{\%}. Throughout the 16-year experience with cardiac transplantation at CPMC, the criteria of eligibility for both donor and recipient candidates have been expanded to include older patients. In addition, pediatric patients requiring complex arterial or venous reconstruction and patients with elevated, but reversible pulmonary vascular resistance have been transplanted with excellent results. With the evolution of prolonged posttransplant survival has come a new group of complications associated with chronic long-term immunosuppressive therapy. These, and issues relating to cardiac retransplantation, continue to increase, largely because of the critical lack of organ donors. Continued efforts are being developed to optimize and reduce the total amount of immunosuppression administered postoperatively. Currently, research interests at CPMC include therapy for transplant coronary artery disease, left ventricular assist devices, and xenotransplantation. Ongoing investigations in these and other areas of transplantation have been established to encourage continued growth both within the field and at CPMC through the 21st century.",
author = "Michler, {Robert E.} and Chen, {J. M.} and Mancini, {D. M.} and K. Reemtsma and Rose, {E. A.}",
year = "1993",
language = "English (US)",
pages = "109--118",
journal = "Clinical transplants",
issn = "0890-9016",
publisher = "UCLA Immunogenetics Center",

}

TY - JOUR

T1 - Sixteen years of cardiac transplantation

T2 - the Columbia Presbyterian Medical Center experience 1977 to 1993.

AU - Michler, Robert E.

AU - Chen, J. M.

AU - Mancini, D. M.

AU - Reemtsma, K.

AU - Rose, E. A.

PY - 1993

Y1 - 1993

N2 - Cardiac transplantation is currently recognized as the best therapy available for the treatment of endstage heart disease. Since 1977, more than 650 cardiac transplants have been performed at CPMC, with a one-year survival rate currently approaching 85% and a 5-year survival rate approaching 65%. Throughout the 16-year experience with cardiac transplantation at CPMC, the criteria of eligibility for both donor and recipient candidates have been expanded to include older patients. In addition, pediatric patients requiring complex arterial or venous reconstruction and patients with elevated, but reversible pulmonary vascular resistance have been transplanted with excellent results. With the evolution of prolonged posttransplant survival has come a new group of complications associated with chronic long-term immunosuppressive therapy. These, and issues relating to cardiac retransplantation, continue to increase, largely because of the critical lack of organ donors. Continued efforts are being developed to optimize and reduce the total amount of immunosuppression administered postoperatively. Currently, research interests at CPMC include therapy for transplant coronary artery disease, left ventricular assist devices, and xenotransplantation. Ongoing investigations in these and other areas of transplantation have been established to encourage continued growth both within the field and at CPMC through the 21st century.

AB - Cardiac transplantation is currently recognized as the best therapy available for the treatment of endstage heart disease. Since 1977, more than 650 cardiac transplants have been performed at CPMC, with a one-year survival rate currently approaching 85% and a 5-year survival rate approaching 65%. Throughout the 16-year experience with cardiac transplantation at CPMC, the criteria of eligibility for both donor and recipient candidates have been expanded to include older patients. In addition, pediatric patients requiring complex arterial or venous reconstruction and patients with elevated, but reversible pulmonary vascular resistance have been transplanted with excellent results. With the evolution of prolonged posttransplant survival has come a new group of complications associated with chronic long-term immunosuppressive therapy. These, and issues relating to cardiac retransplantation, continue to increase, largely because of the critical lack of organ donors. Continued efforts are being developed to optimize and reduce the total amount of immunosuppression administered postoperatively. Currently, research interests at CPMC include therapy for transplant coronary artery disease, left ventricular assist devices, and xenotransplantation. Ongoing investigations in these and other areas of transplantation have been established to encourage continued growth both within the field and at CPMC through the 21st century.

UR - http://www.scopus.com/inward/record.url?scp=0027792070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027792070&partnerID=8YFLogxK

M3 - Article

SP - 109

EP - 118

JO - Clinical transplants

JF - Clinical transplants

SN - 0890-9016

ER -